AIM ImmunoTech Announces Release of the Next CEO Corner Segment
11 April 2024 - 5:00PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), today announced the
next CEO Corner segment has been published on the Company’s
website. For the CEO Corner segment, Thomas Equels, Chief Executive
Officer of AIM ImmunoTech, discussed the Company’s recent news
release regarding top-line interim data indicating that combining
Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the
treatment of recurrent ovarian cancer may have a powerful
synergistic effect that could be far more effective than
pembrolizumab alone as a therapy for the disease.
The CEO Corner segment is now available
here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.For more information,
please visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
Von Sep 2023 bis Sep 2024